Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 18/07/2018 | FDA Grants Bisantrene Rare Paediatric Disease Designation | Download |
| 16/07/2018 | Trading Halt | Download |
| 13/07/2018 | Appendix 3B-Issue of Options | Download |
| 13/07/2018 | Appendix 3B | Download |
| 02/07/2018 | Cleansing Notice | Download |
| 02/07/2018 | Appendix 3B | Download |
| 02/07/2018 | Expiry of Unlisted Options | Download |
| 02/07/2018 | Performance Share Milestones Met | Download |
| 26/06/2018 | Bisantrene poster presented at French Leukaemia Conference | Download |
| 22/06/2018 | Release of Securities from Escrow | Download |
ASX: RAC
Price
Latest News
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene
Proactive Investor interviews John Cullity
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the
Don't miss important updates
Get the latest news & announcement and stay up-to-date.